Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Accumulated Expenses: 2019-2025

Historic Accumulated Expenses for C4 Therapeutics (CCCC) over the last 5 years, with Sep 2025 value amounting to $11.3 million.

  • C4 Therapeutics' Accumulated Expenses fell 26.76% to $11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.3 million, marking a year-over-year decrease of 26.76%. This contributed to the annual value of $19.4 million for FY2024, which is 6.14% down from last year.
  • According to the latest figures from Q3 2025, C4 Therapeutics' Accumulated Expenses is $11.3 million, which was down 16.85% from $13.6 million recorded in Q2 2025.
  • C4 Therapeutics' 5-year Accumulated Expenses high stood at $20.6 million for Q4 2023, and its period low was $6.3 million during Q1 2021.
  • Moreover, its 3-year median value for Accumulated Expenses was $15.4 million (2024), whereas its average is $15.0 million.
  • In the last 5 years, C4 Therapeutics' Accumulated Expenses soared by 71.80% in 2022 and then crashed by 33.03% in 2024.
  • Over the past 5 years, C4 Therapeutics' Accumulated Expenses (Quarterly) stood at $13.6 million in 2021, then spiked by 45.30% to $19.8 million in 2022, then grew by 4.36% to $20.6 million in 2023, then dropped by 6.14% to $19.4 million in 2024, then declined by 26.76% to $11.3 million in 2025.
  • Its Accumulated Expenses stands at $11.3 million for Q3 2025, versus $13.6 million for Q2 2025 and $12.6 million for Q1 2025.